Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Autolus Therapeutics plc

< Previous 1 2 3 Next >
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Provides Business Updates and 2025 Overview
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.